European biotechs: Such a long waitEuropean biotechs have been longly undervalued. In the wake of the COVID-19 pandemic, some of them took off. They will have to prove their value in a post-COVID era. However, Europe is there. more ➔
Harmonisation of patent law without the UP... Hague Court of Appeal (CoA) sets Dutch approach to the doctrine equivalence reversing District Court, handing Eli Lilly another win in its pan-European battle over infringement of its pemetrexed patents … more ➔
Women’s health from niche to mainstr...Women make up half of the world’s population. Finally, pharma companies and invetors are now beginning to pay more attention to female diseases. more ➔
Urgent need for medical data network acros... The COVID-19 pandemic is putting our health systems in Europe to the test. Capacity bottlenecks are becoming apparent, as are long-neglected investments in modern infrastructure. As the pandemic does … more ➔
“The COVID-19 impact was not all bad” Medical Cannabis – Last year, the European Cannabis Association was launched as industry interest group, but than the novel coronavirus pandemic changed everything. European Biotechnology spoke … more ➔
AMR – the silent pandemic that can stil... The COVID-19 pandemic is having a devastating effect on global health and an unprecedented impact on the economy. As the world struggles with the challenges brought on by this pandemic, the threat of … more ➔
Green carbon footprintIn September, Unilever announced a €1bn investment to improve the sustainability of its cleaning brands from the ground up. European Biotechnology spoke to Dr Neil Parry, R&D programme director … more ➔
The role of investors in addressing AMRAbigail Herron from Aviva Investors describes why AMR is a blind spot for investors and which action is needed to change it. more ➔
Protection in case of SPCs for pharmaceuti... SPCs offer up to five and a half years of additional protection after patent expiration for pharmaceuticals in order to compensate the patent holder’s inability to exploit their inventions while products … more ➔
Rentschler Biopharma expands U.S. footprin... Prior to Danish Genmab A/S’s recent licence option deal with AbbVie Inc, Rentschler Biopharma has extended its collaboration with Genmab. European Biotechnology spoke with Rentschler Biopharma SE’s … more ➔
